Merck Halts Trial of Bone Drug After Favorable Results

Merck & Co. rose to its highest value in four years after the company said it will stop testing an experimental drug meant to prevent bone fractures in women with osteoporosis because the therapy worked so well in a trial.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.